News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
HANSOH PHARMA Opens Up ~4%; Upfront Payment USD80M Received After Granting Product License to Regeneron
Blue-chip pharma stock HANSOH PHARMA (03692.HK) opened 3.85% higher today (3rd). It last traded at HKD27, up 3.85%, on a pre-market volume of 70,700 shares, involving HKD1.9083 mil...
Reset
Send
The window will close in 5 seconds
HANSOH PHARMA Opens Up ~4%; Upfront Payment USD80M Received After Granting Product License to Regeneron
Close
Recommend
2
Positive
5
Negative
1
 
SHORT SELL
 
STOCK INFO

Blue-chip pharma stock HANSOH PHARMA (03692.HK)  -0.850 (-3.114%)    Short selling $67.14M; Ratio 28.422%   opened 3.85% higher today (3rd). It last traded at HKD27, up 3.85%, on a pre-market volume of 70,700 shares, involving HKD1.9083 million.

The group announced after market close yesterday (2nd) that it has granted Regeneron (REGN.US)      an exclusive worldwide license (excluding Mainland China, Hong Kong, and Macau) for its investigational dual GLP-1/GIP receptor agonist.

Related NewsUOB Kay Hian Lifts HANSOH PHARMA's TP to HKD40 w/ Buy Rating
HANSOH PHARMA will receive an upfront payment of USD80 million and be eligible to receive up to USD1.93 billion in milestone payments, as well as double-digit royalties on potential future product sales.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-05 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.